JWH-300
JWH-300 is a synthetic cannabinoid that acts as a potent agonist at the CB1 and CB2 cannabinoid receptors. It is part of the JWH series of synthetic cannabinoids, which were developed by Dr. John W. Huffman and his team at Clemson University in the 1990s and early 2000s.
Chemical Structure and Properties[edit | edit source]
JWH-300 is chemically classified as a naphthoylindole, a class of compounds known for their high affinity for cannabinoid receptors. The chemical structure of JWH-300 includes a naphthalene group, which is a bicyclic aromatic hydrocarbon, and a urea linkage, which is a functional group consisting of a carbonyl group attached to two amine groups.
Pharmacology[edit | edit source]
JWH-300 acts as a full agonist at both the CB1 and CB2 receptors, with a higher affinity for the CB2 receptor. This receptor selectivity profile suggests that JWH-300 may have potential therapeutic applications in conditions where CB2 receptor activation is beneficial, such as in inflammation and pain management. However, like many synthetic cannabinoids, JWH-300 can also produce psychoactive effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.
Legal Status[edit | edit source]
The legal status of JWH-300 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. In the United States, JWH-300 and other synthetic cannabinoids are often listed as Schedule I substances under the Controlled Substances Act.
Potential Risks and Side Effects[edit | edit source]
The use of JWH-300, like other synthetic cannabinoids, can be associated with a range of adverse effects. These may include tachycardia, hypertension, anxiety, paranoia, and hallucinations. Long-term use may lead to dependence and withdrawal symptoms upon cessation.
Research and Development[edit | edit source]
Research into JWH-300 and related compounds continues, with a focus on understanding their pharmacological properties and potential therapeutic applications. However, due to their potential for abuse, research is often limited and highly regulated.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
